Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
Journal
Journal of the International AIDS Society
Journal Volume
24
Journal Issue
11
Date Issued
2021
Author(s)
Liou, Bo-Huang
Cheng, Chih-Ning
Lin, Ya-Ting
Lin, Yu-Jou
Liu, Wen-Chun
Abstract
Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI). We aimed to evaluate the effect, safety and tolerability of 1HP in people living with HIV (PLWH) and LTBI who received coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Subjects
drug-drug interaction; integrase strand transfer inhibitor; protein-adjusted 95% effective concentration; rifamycin; trough concentration
SDGs
Publisher
JOHN WILEY & SONS LTD
Type
journal article